TrialPath
Recruiting

Study of PTC844 in Participants With Active Rheumatoid Arthritis

NCT07779616 · PTC Therapeutics
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2A, Proof-of-Concept, Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PTC844 in Participants With Active Rheumatoid Arthritis
About this study
This study is designed to assess the safety, pharmacokinetics (PK), and biomarker effects of PTC844 compared to placebo in participants with active rheumatoid arthritis (RA).
Eligibility criteria
Key Inclusion Criteria: * Historical diagnosis of RA as per the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) diagnostic criteria. * Active RA disease with a threshold of moderate activity or higher as confirmed via DAS28-CRP (score of ≥3.2) at screening. * Naïve to disease-modifying treatments for RA or have had an inadequate response to background treatment for RA and/or inability to tolerate disease-modifying antirheumatic drugs, as per investigator's discretion. * Disease-modifying antirheumatic drugs should be stable and unchanged from 30 days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study. * CRP of ≥5 milligrams (mg)/liter (L) at screening. Key Exclusion Criteria: * Presence of any clinically significant abnormality at screening, or prior or ongoing medical condition (for example, concomitant illness, psychiatric condition), surgical procedure, medical history, or physical findings that, in the investigator's opinion, could adversely affect the safety of the participant or could impair the assessment of study results. * Participants with Class IV RA. * Past medical history of blood dyscrasia, bone marrow abnormality and/or suppression, drug induced thrombocytopenia or idiopathic thrombocytopenia, or bleeding diathesis. * Past medical history of inflammatory joint disease other than RA or fibromyalgia. * Rheumatoid arthritis onset at \<17 years of age. * Past medical history of malignancy within 5 years prior to screening, except for nonmelanoma skin cancers cursed via local resection. * Participant has a known hypersensitivity to any of the ingredients of PTC844 or to any excipients of the study drug. * Use or intended use of any prescribed disease-modifying treatments for RA within 30 days or 5 half-lives (whichever is longer) before the Screening Period until completion of the Follow-Up Visit, except for methotrexate, low dose prednisone (\<10 mg/day), hydroxychloroquine, or sulfasalazine, which are permitted as established background single-therapy medications. * Use or intended use of a combination of methotrexate, low dose prednisone (\<10 mg/day), hydroxychloroquine, or sulfasalazine within 30 days or 5 half-lives (whichever is longer) before the Screening Period until completion of the Follow-Up Visit. Note: Other protocol-defined inclusion/exclusion criteria may apply.
Study design
Enrollment target: 75 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-09-24
Estimated completion: 2027-10-29
Last updated: 2026-11-06
Interventions
Drug: PTC844Drug: Placebo
Primary outcomes
  • • Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline up to Week 16)
  • • Change From Baseline to Week 2 in Dihydroorotate (DHO) (Baseline, Week 2)
Sponsor
PTC Therapeutics · industry
Contacts & investigators
ContactPatient Advocacy · contact · medinfo@ptcbio.com · 1-866-562-4620
All locations (26)
AARA Clinical Research - Arizona Arthritis and Rheumatology Associates - ChandlerRecruiting
Chandler, Arizona, United States
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - FlagstaffNot Yet Recruiting
Flagstaff, Arizona, United States
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - PhoenixNot Yet Recruiting
Phoenix, Arizona, United States
Millennium Clinical TrialsRecruiting
Westlake Village, California, United States
Nouvelle Clinical Research LLCRecruiting
Cutler Bay, Florida, United States
Vitaly Clinical Research, LLCNot Yet Recruiting
Miami, Florida, United States
Millennium Medical Research, LLC.Recruiting
Miami, Florida, United States
Suncoast Clinical Research, Inc. - New Port RicheyNot Yet Recruiting
New Port Richey, Florida, United States
Conquest ResearchRecruiting
Winter Park, Florida, United States
Chicago Arthritis and Regenerative MedicineNot Yet Recruiting
Chicago, Illinois, United States
DJL Clinical Research PLLCNot Yet Recruiting
Charlotte, North Carolina, United States
Rheumatology Specialty CenterNot Yet Recruiting
Willow Grove, Pennsylvania, United States
Precision Comprehensive Clinical Research Solutions - IrvingRecruiting
Irving, Texas, United States
Arthritis & Rheumatism Associates - FairfaxNot Yet Recruiting
Fairfax, Virginia, United States
Aversi Clinic LLCNot Yet Recruiting
Tbilisi, Georgia
JSC JerarsiNot Yet Recruiting
Tbilisi, Georgia
JSC Vian - Iv. Bokeria University HospitalNot Yet Recruiting
Tbilisi, Georgia
JSC VIAN Caraps MedlineNot Yet Recruiting
Tbilisi, Georgia
LTD Caucasus Medical CentreNot Yet Recruiting
Tbilisi, Georgia
LTD InnovaNot Yet Recruiting
Tbilisi, Georgia
The First Medical Center LLCNot Yet Recruiting
Tbilisi, Georgia
CAP Research ltdNot Yet Recruiting
Quatre Bornes, Mauritius
Arthritis Clinical Research Trials CCNot Yet Recruiting
Cape Town, South Africa
Dr IC LouwNot Yet Recruiting
Cape Town, South Africa
Clinresco Centres (Pty) LtdNot Yet Recruiting
Kempton Park, South Africa
Clinical Trials Network - HelderbergNot Yet Recruiting
Somerset West, South Africa
Study of PTC844 in Participants With Active Rheumatoid Arthritis · TrialPath